Related Experiment Videos
The pentapeptide QYNAD does not inhibit neuronal network activity.
F Otto1, B C Kieseier, P Görtz
1Department of Neurology, Heinrich-Heine-University Düisseldorf, Germany.
Summary
The endogenous pentapeptide QYNAD, elevated in multiple sclerosis and Guillain-Barré syndrome, does not affect neuronal network activity. This suggests QYNAD has no significant impact on central nervous system functional disability.
Area of Science:
- Neuroscience
- Neurophysiology
- Pharmacology
Background:
- Controversial data exists on the sodium channel-blocking effect of QYNAD.
- QYNAD levels are elevated in patients with multiple sclerosis and Guillain-Barré syndrome.
- Previous studies showed conflicting results regarding QYNAD's impact on sodium currents.
Purpose of the Study:
- To investigate the neuroactive effects of QYNAD on neuronal networks.
- To compare QYNAD's impact with known sodium channel blockers lidocaine and tetrodotoxin (TTX).
Main Methods:
- Utilized micro-electrode arrays with cultured neuronal networks to assess neuroactivity.
- Compared electrophysiological parameter changes induced by QYNAD, lidocaine, and TTX.
Main Results:
- QYNAD did not alter neuronal network activity.
- Lidocaine and TTX significantly decreased network activity by prolonging interburst intervals.
- Effective concentrations of lidocaine and TTX were consistent with patch-clamp experiments.
Conclusions:
- QYNAD lacks a significant effect on neuronal network function, despite potential mild effects on single-cell sodium currents.
- These findings question the relevance of QYNAD in contributing to central nervous system functional disability.
- Further research is needed to clarify QYNAD's role in neurological conditions.